The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world survival outcomes of patients (pts) treated with 6-weekly pembrolizumab 400mg (pem6w) plus axitinib (axi) for advanced renal cell carcinoma (aRCC).
 
Sonam Ansel
No Relationships to Disclose
 
Mark Stares
No Relationships to Disclose
 
Robert J. Jones
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Elsevier; Ipsen; Janssen; Merck Serono; MSD Oncology; Novartis; Pfizer; QED Therapeutics; Roche/Genentech; Sanofi; WebMD
Consulting or Advisory Role - Myovant Sciences
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Celgene; IPSEN; Janssen; Merck Serono; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Exelixis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen; MSD
 
Stefan N. Symeonides
Consulting or Advisory Role - Bicycle Therapeutics (Inst); Boxer Capital (Inst); Bristol-Myers Squibb (Inst); Duke Street Bio (Inst); Eisai (Inst); Ellipses Pharma (Inst); EUSA Pharma (Inst); MedAnnex (Inst); MSD (Inst); Pfizer/EMD Serono (Inst); Vaccitech (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); Ipsen (Inst)
Research Funding - BiolineRx (Inst); BioNTech (Inst); Boston Pharmaceuticals (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Nouscom (Inst); Nucana (Inst); Roche/Genentech (Inst); Sapience Therapeutics (Inst); Sierra Oncology (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - BioNTech; Bristol-Myers Squibb; Ipsen; MSD
 
Laura Manson
No Relationships to Disclose
 
Anirban Ray-Chaudhuri
No Relationships to Disclose
 
Manreet Randhawa
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Sarah Slater
Travel, Accommodations, Expenses - EUSA ASCO
 
Abeera Devasar
No Relationships to Disclose
 
Jahangeer Malik
Honoraria - Astellas Pharma; BMS GmbH & Co. KG; EUSA Pharma; Pfizer; Pfizer
Consulting or Advisory Role - Eisai; Ipsen
Travel, Accommodations, Expenses - Eisai; Ipsen
 
Aravindhan Sundaramurthy
Stock and Other Ownership Interests - GlaxoSmithKline (I); MSD Oncology (I)
Travel, Accommodations, Expenses - Bayer; MSD Oncology
 
Tony Elliott
No Relationships to Disclose
 
Balaji Venugopal
Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck; MSD Oncology; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer/EMD Serono
Speakers' Bureau - Eisai; Ipsen; Janssen Oncology; MSD Oncology; Pfizer
Research Funding - Calithera Biosciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - EUSA Pharma; Ipsen